Gene Editing Turns Stem Cells Into Antibody-Producing Factories in Mice

Antibody drugs are used to treat chronic infections, cancer and other persistent diseases, but their effects last only weeks. Patients must receive repeated infusions to maintain protection. A study published in the journal Science offers an alternative by editing blood-forming stem cells so the body produces its own antibodies over long periods.

The study edited a small number of blood-forming cells in mice. The immune cells produced from those stem cells carried a genetic blueprint for a selected antibody. Once returned to the body, the edited cells acted as a living factory that could be activated by a matching vaccine booster.

Antibodies are proteins that bind to viruses, cancer cells and other targets. Drug manufacturers produce them in controlled settings, purify the proteins and infuse them into patients. The body clears these antibodies within weeks, leading to high cumulative costs that can reach tens of thousands of dollars per year.

How the Approach Works The method starts with hematopoietic stem cells from bone marrow that generate all red blood cells and immune cells over a lifetime. Researchers inserted the genetic code for a chosen antibody into a specific region of these stem cells responsible for antibody production.

After transplantation back into mice, the edited cells differentiated into white blood cells that produced the target antibody. The system remained largely inactive until a matching vaccine was administered. The edited immune cells then multiplied, matured and produced high levels of the antibody.

A booster shot could increase supply as needed. The experiments used only about 7,000 edited stem cells, far fewer than the millions required in some other gene therapies.

Mice engineered with an HIV-blocking antibody maintained blood levels sufficient to prevent the virus from infecting cells in laboratory tests. In mice given a malaria antibody, the parasite was blocked from entering the liver. Mice equipped with a flu-fighting antibody survived a lethal dose of an influenza strain different from the one used to design the antibody, while all untreated mice died.

The approach also allowed two populations of edited stem cells to produce two distinct antibodies at once. This dual production may help counter rapidly evolving viruses such as HIV by reducing the chance of viral escape. In a separate test, human blood-forming stem cells were edited in the laboratory, transplanted into mice with weakened immune systems and grew into human immune cells that produced the chosen antibody.

The platform can be adapted to produce non-antibody proteins. In one test, engineered cells secreted a fluorescent marker protein along with the antibody. The method could eventually support long-term delivery of missing enzymes for genetic disorders, hormones for metabolic conditions or protein-based cancer treatments.

Antibody levels rose after a vaccine boost and declined on their own, offering a form of control not possible with simple infusions. Future versions could include regulatory switches to adjust production up or down according to patient needs. The edited cells are expected to persist for decades.

Significant challenges remain before any human use. The procedure requires safety testing because the cells will remain in the body long-term. Current methods often involve bone marrow conditioning with chemotherapy, which limits who can receive treatment.

Researchers must confirm that gene editing occurs only at the intended site and that the modified cells do not cause harm over many years. The study shifts the concept of antibody therapy from repeated vial infusions to a one-time cellular modification that lets the body produce medicine when signaled by a vaccine.

The work has been conducted only in mice, and human trials remain years away.